J-Pharma is a drug discovery biotech, with a primary focus on L-type amino acid transporter 1 (LAT1), an essential amino acid transporter discovered by its founder. J-Pharma has two LAT1 inhibitors in its development pipeline. The first compound demonstrated a statistically significant improvement in Ph.2 study for biliary tract cancer, where treatment options are limited. The results were selected for top 5% presenter at two ASCO meetings, one of the largest cancer societies. The company is currently preparing for a global Ph.3 study, and the drug is expected to launch in 2028 with projected peak sales of >1 B USD.